BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24131622)

  • 1. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
    Karlsson E; Pérez-Tenorio G; Amin R; Bostner J; Skoog L; Fornander T; Sgroi DC; Nordenskjöld B; Hallbeck AL; Stål O
    Breast Cancer Res; 2013; 15(5):R96. PubMed ID: 24131622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
    Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
    Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
    Karlsson E; Magić I; Bostner J; Dyrager C; Lysholm F; Hallbeck AL; Stål O; Lundström P
    PLoS One; 2015; 10(12):e0145013. PubMed ID: 26698305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
    Pérez-Tenorio G; Karlsson E; Waltersson MA; Olsson B; Holmlund B; Nordenskjöld B; Fornander T; Skoog L; Stål O
    Breast Cancer Res Treat; 2011 Aug; 128(3):713-23. PubMed ID: 20953835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer.
    Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M
    Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
    Rutkovsky AC; Yeh ES; Guest ST; Findlay VJ; Muise-Helmericks RC; Armeson K; Ethier SP
    BMC Cancer; 2019 May; 19(1):491. PubMed ID: 31122207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.
    Bostner J; Karlsson E; Eding CB; Perez-Tenorio G; Franzén H; Konstantinell A; Fornander T; Nordenskjöld B; Stål O
    Endocr Relat Cancer; 2015 Jun; 22(3):331-43. PubMed ID: 25972244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.
    Sridharan S; Basu A
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
    Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
    J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
    Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R6. PubMed ID: 24447434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
    Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
    Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
    Karlsson E; Veenstra C; Emin S; Dutta C; Pérez-Tenorio G; Nordenskjöld B; Fornander T; Stål O
    Breast Cancer Res Treat; 2015 Aug; 153(1):31-40. PubMed ID: 26208487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
    Bostner J; Karlsson E; Pandiyan MJ; Westman H; Skoog L; Fornander T; Nordenskjöld B; Stål O
    Breast Cancer Res Treat; 2013 Jan; 137(2):397-406. PubMed ID: 23242584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.
    Lehn S; Tobin NP; Sims AH; Stål O; Jirström K; Axelson H; Landberg G
    BMC Cancer; 2014 Feb; 14():119. PubMed ID: 24559095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal expression of p-AMPKa and p-S6 is strongly associated with the prognosis of gastric cancer.
    Zheng Z; Zheng Y; Zhang M; Wang J; Yu G; Fang W
    Tumour Biol; 2016 Apr; 37(4):4803-11. PubMed ID: 26520441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.